Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients

• Status: Completed
• Trial end date: 2010-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to evaluate the efficacy of quetiapine fumarate extended-release (XR) used as mono-therapy, administered once daily, in the treatment of schizophrenic patient with acute episode.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Chlorpromazine; Quetiapine Fumarate

Criteria

Inclusion Criteria:

• Schizophrenia diagnosis

• Provision of written informed consent before initiation of any study

Exclusion Criteria:

• AIDS and hepatitis B

• History of seizure disorder

• Hospitalisation for schizophrenic more than 1 month immediately before enter into study